Back To Search Instructions
Protocols
13 protocols meet the specified criteria
Disease Site: Ovary
Protocol No.TitleStatus
1200000138Biospecimen Repository for Individuals at High Risk for Breast, Ovarian, or Other Hereditary CancersOpen
1404299159Imaging of the ovary with a volume holographic imaging system: pilot studyOpen
1502660379S1316: Prospective Comparative Effectiveness Trial for Malignant Bowel ObstructionOpen
1504771536Continued Recruitment of High-Risk and Low-Risk control subjects to assess biomarkers of ovarian cancer riskOpen
1508036559A Multicentre Randomised Phase II Study of AZD1775 plus Chemotherapy versus Chemotherapy Alone in Patients with Platinum-Resistant TP53-Mutated Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerOpen
1511224935A Randomized, Open-Label Study Comparing the Combination of YONDELIS(R) and DOXIL(R) / CAELYX(R) With DOXIL(R) / CAELYX(R) Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerOpen
1606624652GOG-0281: A RANDOMIZED PHASE II/III STUDY TO ASSESS THE EFFICACY OF TRAMETINIB (GSK 1120212) IN PATIENTS WITH RECURRENT OR PROGRESSIVE LOW-GRADE SEROUS OVARIAN CANCER OR PERITONEAL CANCEROpen
1610935809A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyOpen
1612038226ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerOpen
1704374063A Phase 1 Open-Label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer SubjectsOpen
1704390293A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsOpen
PHXA-15-0002-10-15Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?Open
PHXE-16-0001-80-15FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853} Versus Investigator's Choice of Chemotherapy in Women with Folate Receptor á-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Primary Fallopian Tube CancerOpen